Remepy
Shai Erlich is currently working as the Chief Development Officer at Remepy providing drug development consulting services. Previously, Shai held various roles at Quark Pharmaceuticals including Chief Medical Officer, Vice President, and Director of Research Planning. Shai has a PhD in Human/Medical Genetics and extensive experience in pharmaceutical development and consulting.
This person is not in any offices
Remepy
Remepy is Pioneering Hybrid Drugs™. We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.